II. Indications
- Fertility Treatment - Inhibits premature LH surge in controlled Ovarian Hyperstimulation (women)
- Ganirelix (Fyremadel, Antagon)
- Cetrorelix (Cetrotide)
-
Endometriosis (moderate to severe pain in women)
- Elagolix (Orilissa)
- Advanced Prostate Cancer (Men)
- Degarelix (Firmagon)
- Relugolix (Orgovyx)
- Abarelix (Plenaxis)
III. Contraindications
- Pregnancy
- Osteoporosis
- Severe liver disease (Elagolix)
IV. Mechanism
- Gonadotropin-Releasing Hormone (GnRH)
- GnRH is generated within hypothalamic Neurons (infundibular nucleus, arcuate nucleus)
- GnRH is released typically in pulses in men and women
- GnRH binds receptors on the Pituitary Gland triggering release of gonadotropins
- Gonadotropins (LH, FSH) stimulate release of sex Hormones (e.g. Estrogen, Testosterone)
- GnRH Antagonist
- GnRH Antagonists are synthetic peptides that block GnRH receptors on the surface of Gonadotroph cells in the anterior pituitary
- Decrease LH and FSH release from the anterior Pituitary Gland's Gonadotroph cells
- Results in decreased Estrogen synthesis (ovaries) and Testosterone synthesis (Testes)
- Images
V. Medications: Women
- Elagolix (Orilissa)
- Endometriosis: 150 mg orally once daily (<=24 months, <=6 months in liver disease) or 200 mg orally twice daily (<=6 months)
- Ganirelix (Fyremadel, Antagon)
- Infertility: Start day 5-6 of cycle (after FSH therapy on Day 2-3), giving 250 mcg SQ daily during the mid-late Follicular Phase
- Cetrorelix (Cetrotide)
- Infertility: Start day 5-6 of cycle (after FSH therapy on Day 2-3), giving 0.25 mcg SQ daily during the mid-late Follicular Phase
VI. Medications: Prostate Cancer (Men)
- Degarelix (Firmagon)
- Prostate Cancer: Start with 240 mg SQ, then 80 mg SQ every 28 days
- Relugolix (Orgovyx)
- Prostate Cancer: Start with 360 mg orally day 1, then 120 mg orally daily at same time each day
- Abarelix (Plenaxis)
- Older agent, replaced by newer agents (e.g. Degarelix)
VII. Adverse Effects: Women
- Menopausal symptoms
- Hot Flashes
- Insomnia
- Emotional changes (includes Major Depression)
-
Liver Function Test abnormalities (Elagolix)
- Increased transaminases
- Bone density loss with prolonged use
- Other adverse effects
VIII. Adverse Effects: Prostate Cancer (Men)
- Hypersensitivity including Anaphylaxis (Degarelix, Relugolix)
- QTc Prolongation (Degarelix, Relugolix)
- Bone density loss with prolonged use
-
Liver Function Test abnormalities (Degarelix, Relugolix)
- Increased transaminases
- Other adverse effects
- Injection site reactions (Degarelix)
- Hot Flashes
- Altered bowel habits (Relugolix)
- Musculoskeletal pain (Relugolix)
IX. Safety
- Avoid in Pregnancy
- Avoid in Lactation
X. Drug Interactions
- Strong P-gp Inhibitors (esp. combined with strong CYP3A Inducers)
- Avoid with Relugolix (or separate doses by at least 6 hours)
- OATP 1B1 Inhibitors
- Avoid with Elagolix (significantly increases drug levels)
XI. Resources
- Degarelix (DailyMed)
- Relugolix (DailyMed)
- Elagolix (DailyMed)
- Ganirelix (DailyMed)
- Cetrorelix (DailyMed)
XII. References
- (2022) Presc Lett, Medications to treat Prostate Cancer, Resource #380108
- Fairchild (2015) AJR Am J Roentgenol 204(6):W620-30 +PMID: 26001251 [PubMed]
Images: Related links to external sites (from Bing)
Related Studies
orilissa (on 10/12/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
ORILISSA 150 MG TABLET | $36.15 each | |
ORILISSA 200 MG TABLET | $18.11 each |